Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Drug-induced neutropenia and agranulocytosis

Thomas D Coates, MD
Section Editor
Peter Newburger, MD
Deputy Editor
Alan G Rosmarin, MD


Most cases of neutropenia in adults are acquired and are due to decreased granulocyte production or increased destruction. Neutropenia can be predictable and dose related, as in the case of cytotoxic chemotherapy, or an idiosyncratic reaction. The mechanisms of the neutropenia are varied and the propensity to infection depends upon the adequacy of bone marrow reserve.

Drug-induced neutropenia and agranulocytosis will be reviewed here. Others causes of acquired neutropenia, such as primary immune mechanisms, chemotherapy, and infections, as well as congenital neutropenia in children are discussed separately. (See "Immune neutropenia" and "Infectious causes of neutropenia" and "Congenital neutropenia" and "Overview of neutropenic fever syndromes".)

The overall approach to the patient with neutropenia is discussed separately. (See "Overview of neutropenia in children and adolescents" and "Approach to the adult with unexplained neutropenia".)


Neutropenia is defined as an absolute neutrophil count (ANC) <1500/microL. The ANC is numerically equal to the product of the white blood cell count (WBC) and the fraction of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis (calculator 1):

ANC = (WBC [cells/microL] x percent [PMNs + bands]) ÷ 100

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 01, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007; 146:657.
  2. Hamerschlak N, Montezuma MP, Bacal N, et al. Retrospective prevalence and incidence of drug-induced agranulocytosis in the city of São Paulo-Brasil. Rev Paul Med 1993; 111:294.
  3. Strom BL, Carson JL, Schinnar R, et al. Descriptive epidemiology of agranulocytosis. Arch Intern Med 1992; 152:1475.
  4. Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 1996; 60:23.
  5. Billekop K, Mosbech J. [Mortality from agranulocytosis in Denmark during the period 1958-1972]. Ugeskr Laeger 1976; 138:1697.
  6. Böttiger LE, Furhoff AK, Holmberg L. Drug-induced blood dyscrasias. A ten-year material from the Swedish Adverse Drug Reaction Committee. Acta Med Scand 1979; 205:457.
  7. Wiholm BE, Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol Suppl 1996; 60:42.
  8. Kaufman DW, Kelly JP, Issaragrisil S, et al. Relative incidence of agranulocytosis and aplastic anemia. Am J Hematol 2006; 81:65.
  9. Kaufman DW, Kelly JP, Levy M, et al. The Drug Etiology of Agranulocytosis and Aplastic Anemia, Oxford University Press, New York 1991.
  10. Kaufman DW, Kelly JP, Levy M, et al. Drug etiology of agranulocytosis: Update of the International Agranulocytosis and Aplastic Anemia Study. Pharmacoepidem Drug Safety 1993; 2:S25.
  11. Kantero I, Mustala OO, Palva IP. Drug-induced agranulocytosis, with special reference to aminophenazone. IV. Children. Acta Med Scand 1972; 192:327.
  12. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329:162.
  13. Young NS. Agranulocytosis. JAMA 1994; 271:935.
  14. Levy M, Kelly JP, Kaufman DW, Shapiro S. Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study. Ann Hematol 1993; 67:187.
  15. Sinhvi SM, Duchin KL, Willard DA, et al. Renal handling of captopril: effect of probenecid. Clin Pharmacol Ther 1982; 32:182.
  16. Casato M, Pucillo LP, Leoni M, et al. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. Am J Med 1995; 99:386.
  17. Yunis JJ, Lieberman J, Yunis EJ. Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. Drug Saf 1992; 7 Suppl 1:7.
  18. Corzo D, Yunis JJ, Salazar M, et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995; 86:3835.
  19. Tamai H, Sudo T, Kimura A, et al. Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann Intern Med 1996; 124:490.
  20. Hodinka L, Géher P, Merétey K, et al. Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies. Int Arch Allergy Appl Immunol 1981; 65:460.
  21. Zhu NY, Legatt DF, Turner AR. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med 2009; 150:287.
  22. Centers for Disease Control and Prevention (CDC). Agranulocytosis associated with cocaine use - four States, March 2008-November 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1381.
  23. Muirhead TT, Eide MJ. Images in clinical medicine. Toxic effects of levamisole in a cocaine user. N Engl J Med 2011; 364:e52.
  24. Andrès E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol 2010; 150:3.
  25. Johnston A, Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol 2015; 11:243.
  26. van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159:369.
  27. Andrès E, Zimmer J, Mecili M, et al. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol 2011; 4:143.
  28. Chia HM, Kalra L, Lakhani AK, Samaratunga IR. Filgrastim for low-dose, captopril-induced agranulocytosis. Lancet 1993; 342:304.
  29. Elis A, Lishner M, Lang R, Ravid M. Agranulocytosis associated with enalapril. DICP 1991; 25:461.
  30. Aymard JP, Aymard B, Netter P, et al. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp 1988; 3:430.
  31. List AF, Beaird DH, Kummet T. Ranitidine-induced granulocytopenia: recurrence with cimetidine administration. Ann Intern Med 1988; 108:566.
  32. Brenner LO. Agranulocytosis and ranitidine. Ann Intern Med 1986; 104:896.
  33. Mamus SW, Burton JD, Groat JD, et al. Ibuprofen-associated pure white-cell aplasia. N Engl J Med 1986; 314:624.
  34. Cramer RL, Aboko-Cole VC, Gualtieri RJ. Agranulocytosis associated with etodolac. Ann Pharmacother 1994; 28:458.
  35. Muroi K, Ito M, Sasaki R, et al. Treatment of drug-induced agranulocytosis with granulocyte-colony stimulating factor. Lancet 1989; 2:55.
  36. Colomina P, Garcia S. Agranulocytosis caused by diclofenac. DICP 1989; 23:507.
  37. García S, Belda J, Linares M, et al. Piroxicam-induced agranulocytosis. Drug Intell Clin Pharm 1988; 22:1003.
  38. D'Arcy PF. Risks of agranulocytosis and aplastic anemia with analgesic use. Int Pharm J 1987; 1:87.
  39. Strom BL, Carson JL, Schinnar R, et al. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med 1993; 153:2119.
  40. Rouveix B, Coulombel L, Aymard JP, et al. Amodiaquine-induced immune agranulocytosis. Br J Haematol 1989; 71:7.
  41. Clarke JB, Neftel K, Kitteringham NR, Park BK. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 1991; 95:369.
  42. Soff GA, Kadin ME. Tocainide-induced reversible agranulocytosis and anemia. Arch Intern Med 1987; 147:598.
  43. Volosin K, Greenberg RM, Greenspon AJ. Tocainide associated agranulocytosis. Am Heart J 1985; 109:1392.
  44. Ellrodt AG, Murata GH, Riedinger MS, et al. Severe neutropenia associated with sustained-release procainamide. Ann Intern Med 1984; 100:197.
  45. Samlowski WE, Frame RN, Logue GL. Flecanide-induced immune neutropenia. Documentation of a hapten-mediated mechanism of cell destruction. Arch Intern Med 1987; 147:383.
  46. Vincent MD, Clink HM, Coombes RC, et al. Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer. Br Med J (Clin Res Ed) 1985; 291:105.
  47. Caldwell G, Bradbury A, Toft AD. Aminoglutethimide induced agranulocytosis in breast cancer. Br Med J (Clin Res Ed) 1985; 291:970.
  48. Hörnsten P, Keisu M, Wiholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990; 126:919.
  49. Piga A, Roggero S, Salussolia I, et al. Deferiprone. Ann N Y Acad Sci 2010; 1202:75.
  50. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583.
  51. www.adverse-effects.com/agranulocytosis/case_reports.html (Accessed on October 05, 2011).
  52. Ibáñez L, Vidal X, Ballarín E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165:869.
  53. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997; 337:809.
  54. Gardner I, Zahid N, MacCrimmon D, Uetrecht JP. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol 1998; 53:991.
  55. Naumann R, Felber W, Heilemann H, Reuster T. Olanzapine-induced agranulocytosis. Lancet 1999; 354:566.
  56. Benedetti F, Cavallaro R, Smeraldi E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999; 354:567.
  57. Berdoukas V, Farmaki K, Carson S, et al. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med 2012; 3:119.
  58. Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol 2009; 122:155.
  59. Henter JI, Karlén J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007; 109:5157.
  60. Masera N, Tavecchia L, Longoni DV, et al. Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination. Blood Transfus 2011; 9:462.
  61. Guffy MM, Goeken NE, Burns CP. Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis. Arch Intern Med 1984; 144:1687.
  62. Shiran A, Shechner C, Dickstein G. Propylthiouracil-induced agranulocytosis in four patients previously treated with the drug. JAMA 1991; 266:3129.
  63. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150:621.
  64. Fincher ME, Fariss BL, Plymate SR, et al. Agranulocytosis and a small dose of methimazole. Ann Intern Med 1984; 101:404.
  65. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983; 98:26.
  66. Tamai H, Takaichi Y, Morita T, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol (Oxf) 1989; 30:525.
  67. Keisu M, Ekman E. Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Clinical features, and estimation of its incidence. Eur J Clin Pharmacol 1992; 43:215.
  68. Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995; 15:176.
  69. Farr M, Scott DG, Bacon PA. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs 1986; 32 Suppl 1:49.
  70. Amos RS, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986; 293:420.
  71. Keisu M, Wiholm BE, Palmblad J. Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system. J Intern Med 1990; 228:353.
  72. Andrès E, Maloisel F. Antibiotic-induced agranulocytosis: a monocentric study of 21 cases. Arch Intern Med 2001; 161:2619.
  73. Haushofer A, Halbmayer WM, Prachar H. Neutropenia with ticlopidine plus aspirin. Lancet 1997; 349:474.
  74. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1:1215.
  75. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321:501.
  76. Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28:1236.
  77. Szto GY, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999; 83:138.
  78. Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159:2524.
  79. Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63:2209.
  80. Rozman S, Sonc M, Novakovic BJ. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Leuk Lymphoma 2012; 53:1945.
  81. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89:308.
  82. Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy. Curr Opin Hematol 2011; 18:49.
  83. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47:1013.
  84. Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol 2010; 85:810.
  85. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:279.
  86. Keane C, Nourse JP, Crooks P, et al. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J 2012; 42:1113.
  87. Hincks I, Woodcock BE, Thachil J. Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br J Haematol 2011; 153:411.
  88. Lee KC, Ladizinski B, Federman DG. Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge. Mayo Clin Proc 2012; 87:581.
  89. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 2009; 84:428.
  90. Christie DJ. Specificity of drug-induced immune cytopenias. Transfus Med Rev 1993; 7:230.
  91. Dorr VJ, Cook J. Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (dipyrone). South Med J 1996; 89:612.
  92. Edwards JE, McQuay HJ. Dipyrone and agranulocytosis: what is the risk? Lancet 2002; 360:1438.
  93. Pisciotta AV. Drug-induced agranulocytosis. Peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4:226.
  94. Uetrecht J, Zahid N, Tehim A, et al. Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 1997; 104:117.
  95. Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992; 7 Suppl 1:17.
  96. Uetrecht J, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988; 245:274.
  97. Parent-Massin DM, Sensébé L, Léglise MC, et al. Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases. Drug Saf 1993; 9:463.
  98. Jacobson IM, Kelsey PB, Blyden GT, et al. Sulfasalazine-induced agranulocytosis. Am J Gastroenterol 1985; 80:118.
  99. Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother 2011; 45:629.
  100. Copolov DL, Bell WR, Benson WJ, et al. Clozapine treatment in Australia: a review of haematological monitoring. Med J Aust 1998; 168:495.
  101. Heit W, Heimpel H, Fischer A, Frickhofen N. Drug-induced agranulocytosis: evidence for the commitment of bone marrow haematopoiesis. Scand J Haematol 1985; 35:459.
  102. Meyer-Gessner M, Benker G, Lederbogen S, et al. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 1994; 17:29.
  103. Juliá A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991; 79:366.
  104. Góra-Tybor J, Krykowski E, Robak T. Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF). Arch Immunol Ther Exp (Warsz) 1996; 44:255.
  105. Tajiri J, Noguchi S, Murakami N. Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. Thyroid 1997; 7:575.
  106. Wickramanayake PD, Scheid C, Josting A, et al. Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis. Eur J Med Res 1995; 1:153.
  107. Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1993; 3:305.
  108. Andrès E, Kurtz JE, Martin-Hunyadi C, et al. Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am J Med 2002; 112:460.
  109. Mossad SB. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008; 148:320; author reply 320.
  110. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999; 9:29.